The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.
Rosetta's test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
In a final policy on comprehensive genomic profiling, Palmetto said that approved registries will have to commit to sharing data, among other requirements.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
GeneNews' early patient risk stratification tests for colorectal, lung, and prostate cancers will be offered to patients at NueHealth's provider-owned care centers.
The draft LCD comes one week after Noridian issued its own draft determination on the test.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
A recent draft local coverage determination from Medicare contractor Noridian is one step along a growth path, according to Veracyte's CEO.
The company said it plans to use the proceeds of the offering for general corporate purposes.
Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.
The firm expects the final LCD will go into effect around the beginning of next year, and that three remaining Medicare contractors will soon post draft LCDs for its test.
With the inclusion of ConfirmMDx in the Medi-Cal program, MDxHealth will seek access for the test in other state Medicaid programs.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The pre-market approval application is based on data collected during a two-year prospective study of more than 33,000 women.
Under the collaboration, University of Victoria researchers will add 2,000 new multiple reaction-monitoring mass spec assays to the CPTAC Assay Portal.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The company recently closed a $7 million funding round and added to its executive team as it aims for a 2017 launch for its test.